Healthcare

Compumedics Limited (ASX:CMP) develops and manufactures diagnostic equipment and software for sleep disorders, neurological monitoring, brain research and ultrasonic blood-flow applications. Its 2026 activity combines established laboratory sleep systems with portable monitoring, digital analysis and broader clinical workflows. High-resolution polysomnography is central to that …

Cochlear Limited (ASX:COH) develops implantable hearing solutions, including cochlear implants and bone conduction systems, alongside replacement sound processors and related services. Its FY26 reporting highlights the relationship between implant adoption, clinical referral practices and financial performance, with efforts to make adult hearing-loss assessment and …

The company’s diagnostic approach incorporates CXCL10, a chemokine biomarker associated with ovarian cancer, within a broader blood-test platform. The pre-surgical test is intended to help distinguish potentially malignant conditions from benign causes of an ovarian mass. Its role is diagnostic assessment ahead of treatment …

A conventional arm-cuff reading measures pressure in peripheral arteries. Central aortic pressure relates to pressure closer to the heart and can provide different information about arterial function. SphygmoCor technology analyses pulse waveforms to derive central cardiovascular measurements. The distinction is important: derived central measures …

CSL Limited (ASX:CSL) develops, manufactures and supplies medicines for serious and rare diseases, alongside influenza vaccines, through CSL Behring, CSL Vifor and CSL Seqirus. Its operations cover plasma-derived therapies, recombinant and gene-based treatments, nephrology products and vaccine manufacturing. FY26 results placed renewed emphasis on …

Clarity Pharmaceuticals (ASX:CU6) is a clinical-stage radiopharmaceutical company developing targeted copper-based products for the diagnosis and treatment of cancer. Its research centres on a sarcophagine, or SAR, chelator that binds copper radioisotopes to cancer-targeting molecules. During 2026, the company reported progress in the SECuRE …

EPP is a rare disorder in which exposure to light can provoke painful phototoxic reactions. SCENESSE is a controlled-release implant administered by appropriately trained healthcare professionals. Its active ingredient, afamelanotide, acts on the melanocortin system and stimulates eumelanin production, a component of the body’s …